A modified anthrax toxin-based enzyme-linked immunospot assay reveals robust T cell responses in symptomatic and asymptomatic Ebola virus exposed individuals.
<h4>Background</h4>Ebola virus (EBOV) caused more than 11,000 deaths during the 2013-2016 epidemic in West Africa without approved vaccines or immunotherapeutics. Despite its high lethality in some individuals, EBOV infection can produce little to no symptoms in others. A better understa...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2018-05-01
|
| Series: | PLoS Neglected Tropical Diseases |
| Online Access: | https://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0006530&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849765081112379392 |
|---|---|
| author | Bobby Brooke Herrera Donald J Hamel Philip Oshun Rolake Akinsola Alani S Akanmu Charlotte A Chang Philomena Eromon Onikepe Folarin Kayode T Adeyemi Christian T Happi Yichen Lu Folasade Ogunsola Phyllis J Kanki |
| author_facet | Bobby Brooke Herrera Donald J Hamel Philip Oshun Rolake Akinsola Alani S Akanmu Charlotte A Chang Philomena Eromon Onikepe Folarin Kayode T Adeyemi Christian T Happi Yichen Lu Folasade Ogunsola Phyllis J Kanki |
| author_sort | Bobby Brooke Herrera |
| collection | DOAJ |
| description | <h4>Background</h4>Ebola virus (EBOV) caused more than 11,000 deaths during the 2013-2016 epidemic in West Africa without approved vaccines or immunotherapeutics. Despite its high lethality in some individuals, EBOV infection can produce little to no symptoms in others. A better understanding of the immune responses in individuals who experienced minimally symptomatic and asymptomatic infection could aid the development of more effective vaccines and antivirals against EBOV and related filoviruses.<h4>Methodology/principle findings</h4>Between August and November 2017, blood samples were collected from 19 study participants in Lagos, Nigeria, including 3 Ebola virus disease (EVD) survivors, 10 individuals with documented close contact with symptomatic EVD patients, and 6 control healthcare workers for a cross-sectional serosurvey and T cell analysis. The Lagos samples, as well as archived serum collected from healthy individuals living in surrounding areas of the 1976 Democratic Republic of Congo (DRC) epidemic, were tested for EBOV IgG using commercial enzyme-linked immunosorbent assays (ELISAs) and Western blots. We detected antibodies in 3 out of 3 Lagos survivors and identified 2 seropositive individuals not known to have ever been infected. Of the DRC samples tested, we detected antibodies in 9 out of 71 (12.7%). To characterize the T cell responses in the Lagos samples, we developed an anthrax toxin-based enzyme-linked immunospot (ELISPOT) assay. The seropositive asymptomatic individuals had T cell responses against EBOV nucleoprotein, matrix protein, and glycoprotein 1 that were stronger in magnitude compared to the survivors.<h4>Conclusion/significance</h4>Our data provide further evidence of EBOV exposure in individuals without EVD-like illness and, for the first time, demonstrate that these individuals have T cell responses that are stronger in magnitude compared to severe cases. These findings suggest that T cell immunity may protect against severe EVD, which has important implications for vaccine development. |
| format | Article |
| id | doaj-art-f357f06e159d42ea997d7eef49ed79bb |
| institution | DOAJ |
| issn | 1935-2727 1935-2735 |
| language | English |
| publishDate | 2018-05-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS Neglected Tropical Diseases |
| spelling | doaj-art-f357f06e159d42ea997d7eef49ed79bb2025-08-20T03:04:58ZengPublic Library of Science (PLoS)PLoS Neglected Tropical Diseases1935-27271935-27352018-05-01125e000653010.1371/journal.pntd.0006530A modified anthrax toxin-based enzyme-linked immunospot assay reveals robust T cell responses in symptomatic and asymptomatic Ebola virus exposed individuals.Bobby Brooke HerreraDonald J HamelPhilip OshunRolake AkinsolaAlani S AkanmuCharlotte A ChangPhilomena EromonOnikepe FolarinKayode T AdeyemiChristian T HappiYichen LuFolasade OgunsolaPhyllis J Kanki<h4>Background</h4>Ebola virus (EBOV) caused more than 11,000 deaths during the 2013-2016 epidemic in West Africa without approved vaccines or immunotherapeutics. Despite its high lethality in some individuals, EBOV infection can produce little to no symptoms in others. A better understanding of the immune responses in individuals who experienced minimally symptomatic and asymptomatic infection could aid the development of more effective vaccines and antivirals against EBOV and related filoviruses.<h4>Methodology/principle findings</h4>Between August and November 2017, blood samples were collected from 19 study participants in Lagos, Nigeria, including 3 Ebola virus disease (EVD) survivors, 10 individuals with documented close contact with symptomatic EVD patients, and 6 control healthcare workers for a cross-sectional serosurvey and T cell analysis. The Lagos samples, as well as archived serum collected from healthy individuals living in surrounding areas of the 1976 Democratic Republic of Congo (DRC) epidemic, were tested for EBOV IgG using commercial enzyme-linked immunosorbent assays (ELISAs) and Western blots. We detected antibodies in 3 out of 3 Lagos survivors and identified 2 seropositive individuals not known to have ever been infected. Of the DRC samples tested, we detected antibodies in 9 out of 71 (12.7%). To characterize the T cell responses in the Lagos samples, we developed an anthrax toxin-based enzyme-linked immunospot (ELISPOT) assay. The seropositive asymptomatic individuals had T cell responses against EBOV nucleoprotein, matrix protein, and glycoprotein 1 that were stronger in magnitude compared to the survivors.<h4>Conclusion/significance</h4>Our data provide further evidence of EBOV exposure in individuals without EVD-like illness and, for the first time, demonstrate that these individuals have T cell responses that are stronger in magnitude compared to severe cases. These findings suggest that T cell immunity may protect against severe EVD, which has important implications for vaccine development.https://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0006530&type=printable |
| spellingShingle | Bobby Brooke Herrera Donald J Hamel Philip Oshun Rolake Akinsola Alani S Akanmu Charlotte A Chang Philomena Eromon Onikepe Folarin Kayode T Adeyemi Christian T Happi Yichen Lu Folasade Ogunsola Phyllis J Kanki A modified anthrax toxin-based enzyme-linked immunospot assay reveals robust T cell responses in symptomatic and asymptomatic Ebola virus exposed individuals. PLoS Neglected Tropical Diseases |
| title | A modified anthrax toxin-based enzyme-linked immunospot assay reveals robust T cell responses in symptomatic and asymptomatic Ebola virus exposed individuals. |
| title_full | A modified anthrax toxin-based enzyme-linked immunospot assay reveals robust T cell responses in symptomatic and asymptomatic Ebola virus exposed individuals. |
| title_fullStr | A modified anthrax toxin-based enzyme-linked immunospot assay reveals robust T cell responses in symptomatic and asymptomatic Ebola virus exposed individuals. |
| title_full_unstemmed | A modified anthrax toxin-based enzyme-linked immunospot assay reveals robust T cell responses in symptomatic and asymptomatic Ebola virus exposed individuals. |
| title_short | A modified anthrax toxin-based enzyme-linked immunospot assay reveals robust T cell responses in symptomatic and asymptomatic Ebola virus exposed individuals. |
| title_sort | modified anthrax toxin based enzyme linked immunospot assay reveals robust t cell responses in symptomatic and asymptomatic ebola virus exposed individuals |
| url | https://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0006530&type=printable |
| work_keys_str_mv | AT bobbybrookeherrera amodifiedanthraxtoxinbasedenzymelinkedimmunospotassayrevealsrobusttcellresponsesinsymptomaticandasymptomaticebolavirusexposedindividuals AT donaldjhamel amodifiedanthraxtoxinbasedenzymelinkedimmunospotassayrevealsrobusttcellresponsesinsymptomaticandasymptomaticebolavirusexposedindividuals AT philiposhun amodifiedanthraxtoxinbasedenzymelinkedimmunospotassayrevealsrobusttcellresponsesinsymptomaticandasymptomaticebolavirusexposedindividuals AT rolakeakinsola amodifiedanthraxtoxinbasedenzymelinkedimmunospotassayrevealsrobusttcellresponsesinsymptomaticandasymptomaticebolavirusexposedindividuals AT alanisakanmu amodifiedanthraxtoxinbasedenzymelinkedimmunospotassayrevealsrobusttcellresponsesinsymptomaticandasymptomaticebolavirusexposedindividuals AT charlotteachang amodifiedanthraxtoxinbasedenzymelinkedimmunospotassayrevealsrobusttcellresponsesinsymptomaticandasymptomaticebolavirusexposedindividuals AT philomenaeromon amodifiedanthraxtoxinbasedenzymelinkedimmunospotassayrevealsrobusttcellresponsesinsymptomaticandasymptomaticebolavirusexposedindividuals AT onikepefolarin amodifiedanthraxtoxinbasedenzymelinkedimmunospotassayrevealsrobusttcellresponsesinsymptomaticandasymptomaticebolavirusexposedindividuals AT kayodetadeyemi amodifiedanthraxtoxinbasedenzymelinkedimmunospotassayrevealsrobusttcellresponsesinsymptomaticandasymptomaticebolavirusexposedindividuals AT christianthappi amodifiedanthraxtoxinbasedenzymelinkedimmunospotassayrevealsrobusttcellresponsesinsymptomaticandasymptomaticebolavirusexposedindividuals AT yichenlu amodifiedanthraxtoxinbasedenzymelinkedimmunospotassayrevealsrobusttcellresponsesinsymptomaticandasymptomaticebolavirusexposedindividuals AT folasadeogunsola amodifiedanthraxtoxinbasedenzymelinkedimmunospotassayrevealsrobusttcellresponsesinsymptomaticandasymptomaticebolavirusexposedindividuals AT phyllisjkanki amodifiedanthraxtoxinbasedenzymelinkedimmunospotassayrevealsrobusttcellresponsesinsymptomaticandasymptomaticebolavirusexposedindividuals AT bobbybrookeherrera modifiedanthraxtoxinbasedenzymelinkedimmunospotassayrevealsrobusttcellresponsesinsymptomaticandasymptomaticebolavirusexposedindividuals AT donaldjhamel modifiedanthraxtoxinbasedenzymelinkedimmunospotassayrevealsrobusttcellresponsesinsymptomaticandasymptomaticebolavirusexposedindividuals AT philiposhun modifiedanthraxtoxinbasedenzymelinkedimmunospotassayrevealsrobusttcellresponsesinsymptomaticandasymptomaticebolavirusexposedindividuals AT rolakeakinsola modifiedanthraxtoxinbasedenzymelinkedimmunospotassayrevealsrobusttcellresponsesinsymptomaticandasymptomaticebolavirusexposedindividuals AT alanisakanmu modifiedanthraxtoxinbasedenzymelinkedimmunospotassayrevealsrobusttcellresponsesinsymptomaticandasymptomaticebolavirusexposedindividuals AT charlotteachang modifiedanthraxtoxinbasedenzymelinkedimmunospotassayrevealsrobusttcellresponsesinsymptomaticandasymptomaticebolavirusexposedindividuals AT philomenaeromon modifiedanthraxtoxinbasedenzymelinkedimmunospotassayrevealsrobusttcellresponsesinsymptomaticandasymptomaticebolavirusexposedindividuals AT onikepefolarin modifiedanthraxtoxinbasedenzymelinkedimmunospotassayrevealsrobusttcellresponsesinsymptomaticandasymptomaticebolavirusexposedindividuals AT kayodetadeyemi modifiedanthraxtoxinbasedenzymelinkedimmunospotassayrevealsrobusttcellresponsesinsymptomaticandasymptomaticebolavirusexposedindividuals AT christianthappi modifiedanthraxtoxinbasedenzymelinkedimmunospotassayrevealsrobusttcellresponsesinsymptomaticandasymptomaticebolavirusexposedindividuals AT yichenlu modifiedanthraxtoxinbasedenzymelinkedimmunospotassayrevealsrobusttcellresponsesinsymptomaticandasymptomaticebolavirusexposedindividuals AT folasadeogunsola modifiedanthraxtoxinbasedenzymelinkedimmunospotassayrevealsrobusttcellresponsesinsymptomaticandasymptomaticebolavirusexposedindividuals AT phyllisjkanki modifiedanthraxtoxinbasedenzymelinkedimmunospotassayrevealsrobusttcellresponsesinsymptomaticandasymptomaticebolavirusexposedindividuals |